Understanding how specific gene fusions contribute to blood cancers
Official title: Elucidating the molecular mechanism of Daple- FLT3 and Daple-PDGFRB gene fusion in blood cancers
Funded at California State Poly U Pomona · NIH-10861830 · Data updated 2026-11-12
This study is looking at how certain gene changes in blood cancers like leukemia can make the disease worse and help find new ways to treat patients who aren't getting better with current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | California State Poly U Pomona NIH-funded |
| Lab location | 1 site (Pomona, United States) |
| Project start | July 15, 2022 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $183,750 |
| NIH project number | 5R16GM146720-03 |
| Project ID | NIH-10861830 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with blood cancers, particularly those with mutations in the FLT3 and PDGFRB genes.
✕Less likely to help
Patients with blood cancers that do not involve the FLT3 or PDGFRB mutations may not benefit from this research.
What this research studies
This research investigates the molecular mechanisms behind gene fusions involving Daple, FLT3, and PDGFRB in blood cancers like leukemia. By examining how these gene fusions lead to the activation of critical signaling pathways that promote cancer progression, the study aims to uncover new therapeutic targets. The approach includes analyzing mutations that cause resistance to existing treatments, which could help in developing more effective therapies for patients who do not respond to current medications.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments that are more effective for patients with blood cancers, particularly those who have developed resistance to existing therapies.
How similar studies have gone: Previous research has shown success in targeting receptor tyrosine kinases in cancer treatment, indicating that this approach has potential for meaningful advancements.
Where this research is happening
-
California State Poly U Pomona
Pomona, United States Active
Researchers
- Principal investigator: Ear, Jason — California State Poly U Pomona
- Study coordinator: Ear, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.